Ipamorelin/CJC-1295 Blend 10mg v2
Pre-blended stack for comparative research work.
Pre-blended Ipamorelin + CJC-1295 research stack — the canonical dual-pathway GH-axis combination. GHRH analog + ghrelin receptor agonist co-lyophilized in a single vial.
Proposed mechanism
CJC-1295 drives GH release through the GHRH receptor; ipamorelin amplifies release through the separate ghrelin (GHS-R1a) receptor. Activating both pathways is reported to produce greater GH pulses than either compound alone.
Research highlights
- Dual-pathway GH research stack
- Co-lyophilized 5 mg + 5 mg
- Each component COA-verified
- Single-reconstitution convenience
Research protocol notes
Protocols using the CJC-1295 No DAC version typically align multiple daily pulses to mimic physiological GH release.
Stacking and comparative studies
Pre-stacked — typically studied as-is.
Handling and storage
Lyophilized powder is stable at ambient shipping temperatures. Once reconstituted with bacteriostatic water, store at 2–8 °C and use within 28 days. For long-term storage of unreconstituted vials, freeze at −20 °C and protect from light.
Frequently asked
Is this the "No DAC" version?
Yes — pre-blended CJC-1295 stacks use the No DAC variant to match ipamorelin pulsing. The long-acting DAC version is not typically co-blended.
Why combine the two?
Different receptors — GHRH and ghrelin — drive GH release through orthogonal pathways. Combined activation produces research-reported synergistic release.
How often is it dosed in research?
Multi-daily pulsing is standard to mimic natural GH release rhythms.
What does the v2 version differ from?
The v2 uses the same compounds in slightly different lyophilization or ratio — see the product page specs for exact composition.
